Can you take Carbidopa / levodopa with Lazertinib?

The levodopa in carbidopa / levodopa has a major potential interaction with Asthma.

Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.

The levodopa in carbidopa / levodopa has a major potential interaction with Cardiovascular Conditions and Disorders.

Cardiac irregularities occur infrequently in patients on dopamine agonists. The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care. Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.

The levodopa in carbidopa / levodopa has a major potential interaction with COPD.

Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.

The carbidopa in carbidopa / levodopa has a moderate potential interaction with Depression.

Caution and observation is recommended when treating patients with carbidopa, as depression with concomitant suicidal tendencies may develop or be exacerbated.

The levodopa in carbidopa / levodopa has a moderate potential interaction with Gastrointestinal Hemorrhage.

The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage. Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.

The carbidopa in carbidopa / levodopa has a major potential interaction with Glaucoma, Narrow Angle.

Carbidopa-levodopa products are contraindicated in patients with narrow-angle glaucoma.

The levodopa in carbidopa / levodopa has a major potential interaction with Glaucoma/Intraocular Hypertension.

The use of levodopa is contraindicated in patients with acute closed-angle glaucoma. Levodopa (with or without carbidopa) may be used in patients with open-angle glaucoma who are receiving appropriate therapy.

The carbidopa and levodopa in carbidopa / levodopa both have a moderate potential interaction with Hypotension.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension at any time, but especially during dose escalation. Additionally, patients with Parkinson's disease may have an impaired capacity to respond to an orthostatic challenge. For these reasons, patients with Parkinson's disease (or restless legs syndrome) who are being treated with dopaminergic agonists typically require careful monitoring for signs/symptoms of orthostatic hypotension, especially during dose escalation, and should be advised of this risk.

Lazertinib has a moderate potential interaction with Interstitial Lung Disease.

Lazertinib, which is administered in combination with amivantamab, can cause interstitial lung disease (ILD)/pneumonitis. Patients should be monitored for worsening or new symptoms indicative of ILD/pneumonitis, such as dyspnea, cough or fever.

The levodopa in carbidopa / levodopa has a major potential interaction with Liver Disease.

The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment. Therapy with levodopa should be administered cautiously in patients with liver or disease. Periodic monitoring of hepatic and renal function is recommended during extended therapy.

Lazertinib has a moderate potential interaction with Liver Disease.

Lazertinib has not been studied in patients with severe hepatic impairment (total bilirubin greater than 3 x upper limit of normal and any AST).

The levodopa in carbidopa / levodopa has a major potential interaction with Psychosis.

The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality. Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.

The carbidopa and levodopa in carbidopa / levodopa both have a moderate potential interaction with Psychosis.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinsonian agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs. The use of bromocriptine in patients with severe psychotic disorders is not recommended.

The levodopa in carbidopa / levodopa has a major potential interaction with Renal Dysfunction.

The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment. Therapy with levodopa should be administered cautiously in patients with liver or disease. Periodic monitoring of hepatic and renal function is recommended during extended therapy.

Lazertinib has a moderate potential interaction with Renal Dysfunction.

Lazertinib has not been studied in patients with severe renal dysfunction or end-stage renal disease (eGFR less than 30 mL/min).

The levodopa in carbidopa / levodopa has a major potential interaction with Skin Cancer.

The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions. Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.

The carbidopa and levodopa in carbidopa / levodopa both have a moderate potential interaction with Sleep Disorders.

Patients treated with products containing carbidopa and levodopa report excessive somnolence and falling asleep while engaged in daily activities, sometimes with no warning sign of drowsiness. Advise patients about the risks, especially those suffering from sleep disorders or using concomitant sedating medications.

Lazertinib has a moderate potential interaction with Visual Defect/Disturbance.

Lazertinib, which is administered in combination with amivantamab, can cause ocular toxicity, including keratitis. Patients should be monitored for new or worsening eye symptoms and referred promptly to an ophthalmologist.